Describing data from preclinical studies and early clinical trial results, Azad et al. suggest that low-dose epigenetic-modulating agents can reprogramme tumour cells and override any immediate cytotoxic effects that are typically observed at high doses. Such optimization of drug dosing and scheduling of currently available epigenetic therapies could give these agents a prominent place in cancer management—when used alone or in combination with other therapies.
- Nilofer Azad
- Cynthia A. Zahnow
- Stephen B. Baylin
